Smith & Nephew plc (ETR:NPW1)
Germany · Delayed Price · Currency is EUR | Market Cap | 10.87B +0.3% |
| Revenue (ttm) | 5.25B +6.1% |
| Net Income | 532.31M +51.7% |
| EPS | 0.61 +52.3% |
| Shares Out | n/a |
| PE Ratio | 20.42 |
| Forward PE | 13.43 |
| Dividend | 0.34 (2.75%) |
| Ex-Dividend Date | Mar 26, 2026 |
| Volume | n/a |
| Average Volume | 164 |
| Open | 12.80 |
| Previous Close | 12.50 |
| Day's Range | 12.80 - 12.80 |
| 52-Week Range | 12.30 - 16.57 |
| Beta | n/a |
| RSI | 35.18 |
| Earnings Date | Aug 4, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew price target lowered to $30 from $32 at Canaccord
Canaccord lowered the firm’s price target on Smith & Nephew to $30 from $32 and keeps a Hold rating on the shares. The firm updated its model following Q1 results…
Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein
Bernstein lowered the firm’s price target on Smith & Nephew to $31.85 from $36.20 and keeps a Market Perform rating on the shares after the company provided a Q1 trading…
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Cevian Capital II GP LTD Acquires Significant Stake in Smith & Nephew PLC
Smith & Nephew and Four More Stocks See Action From Activist Investors
Smith & Nephew To Repurchase Up To $250 Mln Of Shares
(RTTNews) - Smith & Nephew PLC (SNN, SN.L), a medical technology company, said on Friday that it has inked a deal with Merrill Lynch International to repurchase up to $250 million of shares at $0.20 p...
Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,350 GBp from 1,300 GBp and keeps an Equal Weight rating on the shares. Th firm updated the company’s
Smith & Nephew Earnings Call Transcript: Q1 2026
Q1 delivered 3.1% underlying growth, led by Sports Medicine and resilient Advanced Wound Management, offsetting softness in U.S. knees. Full-year guidance is reaffirmed, with a $500 million share buyback announced and strong cash generation supporting future growth.
UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annu...
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming Europ...
Is Smith & Nephew PLC (SNN) a Bargain After 3.1% Drop? GF Value Says Undervalued
Is Smith & Nephew PLC (SNN) a Bargain After 3.1% Drop? GF Value Says Undervalued
Smith & Nephew price target lowered to $32 from $35 at Canaccord
Canaccord analyst Caitlin Cronin lowered the firm’s price target on Smith & Nephew to $32 from $35 and keeps a Hold rating on the shares. The firm updated its model
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
A Look at Smith & Nephew PLC (SNN) After 4.0% Decline -- GF Value $31.12 vs Price $32.84
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith+Nephew (SNN) Reports Positive Trial Results for Cartilage Repair Implant
Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
Smith+Nephew announces further evidence from a multicenter, randomized controlled trial highlighting the clinical superiority of its Cartiheal Agili-C Cartilage Repair Implant recently published in th...
Smith & Nephew Breaks Above 200-Day Moving Average - Bullish for SNN
In trading on Tuesday, shares of Smith & Nephew plc (Symbol: SNN) crossed above their 200 day moving average of $34.14, changing hands as high as $34.41 per share. Smith & Nephew plc shares are curren...
Smith & Nephew reports positive trial data for Regeneten implant
Smith & Nephew announced compelling new randomized control trial data confirming significant outcome improvements for patients with partial-thickness rotator cuff tears treated with the Regeneten bioi...
Smith & Nephew price target raised to 1,507 GBp from 1,482 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on Smith & Nephew to 1,507 GBp from 1,482 GBp and keeps an Overweight rating on the shares.
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed...
Smith & Nephew price target raised to $35 from $34 at Canaccord
Canaccord raised the firm’s price target on Smith & Nephew to $35 from $34 and keeps a Hold rating on the shares. The firm said they delivered a solid quarter,
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Smith+Nephew announces it will feature handheld robotics during the American Academy of Orthopedic Surgeons (AAOS) Annual meeting in New Orleans this week.
Smith & Nephew price target raised to 1,305 GBp from 1,290 GBp at Barclays
Barclays raised the firm’s price target on Smith & Nephew to 1,305 GBp from 1,290 GBp and keeps an Equal Weight rating on the shares.
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase it...
Smith & Nephew Earnings Call Transcript: Q4 2025
Delivered strong FY2025 results with 5.3% revenue growth, 160 bps margin expansion, and $840M free cash flow. 2026 guidance targets 6% organic revenue growth and $1.3B trading profit, with innovation and new launches driving performance.
UK medical products maker Smith & Nephew's annual profit jumps 15.5%
British medical products maker Smith & Nephew posted a 15.5% jump in annual profit on Monday, building on the success of its turnaround plans, which delivered cost savings and boosted growth across it...
Smith & Nephew announces U.S. distribution agreement with RMR Ortho
Smith+Nephew announces it has signed an exclusive U.S. distribution agreement with RMR Ortho to add the A’TOMIC Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand &